Investors Holding Over $100K in Regeneron May Seek to Lead Class Action Lawsuit
Regeneron Class Action Lawsuit: What You Need to Know
Recently, the Rosen Law Firm, a prominent global investor rights firm, has made an important announcement for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Those who purchased Regeneron securities from November 2, 2023, to October 30, 2024, may be eligible to lead a class action lawsuit aimed at seeking justice for their investments. The law firm has set a critical deadline of March 10, 2025, for investors wishing to assume the role of lead plaintiff. This article will outline the key aspects of this class action, the process involved, and the allegations against Regeneron.
What You Need to Do
Investors who purchased shares of Regeneron during the stated class period can take part in this legal initiative without bearing any out-of-pocket fees or costs due to a contingency fee arrangement. This setup means that law firms representing investors only get paid if a recovery is achieved. If you're interested in joining the lawsuit, you can fill out a submission form on the Rosen Law Firm's website or contact their office directly. It is essential to act quickly as the deadline to file as a lead plaintiff is fast approaching.
Why Choose Rosen Law Firm?
Selecting the right legal representation is crucial in any class action lawsuit. The Rosen Law Firm boasts a solid reputation for its track record of success in representing investors. They have been recognized for their outstanding accomplishments and expertise in securities class actions, having facilitated significant settlements in prior cases, including noteworthy achievements against major corporations. Their experience positions them as a reliable choice for investors seeking to take legal action against Regeneron.
The Allegations Against Regeneron
The lawsuit maintains that during the class period, Regeneron's executives made misleading statements that impacted the company's stock performance. Specifically, the complaint alleges several serious infractions, including:
1. Concealed Payments: Regeneron is accused of failing to disclose payments made to distributors, which enabled them to sell Eylea—a mainstay product—at inflated prices.
2. Misleading Sales Reports: These undisclosed payments are said to have artificially boosted reported sales of Eylea, misleading investors and creating a false image of financial health.
3. Impact on Pricing: The allegations further reveal that the misleading statements inflated the Average Sales Price (ASP) of Eylea as reported to federal agencies, ultimately violating the False Claims Act.
4. Market Reaction: When the facts eventually came to light, investors faced substantial losses as the stock price reflected the reality of the situation.
These allegations underscore the seriousness of the case and why affected investors are rallying to hold Regeneron accountable for its actions.
Next Steps for Investors
If you believe you are eligible, it's imperative to act promptly and gather any necessary documentation that demonstrates your investment in Regeneron during the specified period. Investors should also consider the potential benefits of participating in the class action, as it allows for shared legal resources and the ability to collectively contest wrongful corporate behavior.
Conclusion
The upcoming deadline for the Regeneron class action lawsuit presents a critical opportunity for investors who experienced significant losses. With the backing of the Rosen Law Firm, those affected can stand a better chance of achieving a favorable outcome. Remember, the legal landscape can be complex, so it's essential to stay informed and prepared as you navigate this process. Investors are encouraged to keep following updates provided by law firms and monitor any developments regarding the lawsuit. For additional information and the next steps, interested parties can reach out to Phillip Kim of the Rosen Law Firm or visit their website.
Stay alert, and do not miss out on this chance to take a stand if you are a Regeneron investor who has been adversely affected by the company's actions.